阿帕贝特联合标准治疗对近期急性冠脉综合征合并2型糖尿病患者主要不良心血管事件的影响:一项随机临床试验
该随机、双盲、安慰剂对照试验在13个国家190个中心纳入2425例近期(7-90天内)发生急性冠脉综合征、合并2型糖尿病且高密度脂蛋白胆固醇水平低的患者,按1:1随机接受阿帕贝特100 mg口服每日两次(n=1215)或匹配安慰剂(n=1210),均联合标准治疗。主要终点为心血管死亡、非致死性心肌梗死或卒中首次发生的复合终点。中位随访26.5个月,阿帕贝特组主要终点发生125例(10.3%),安慰剂组149例(12.4%),HR 0.82(95%CI 0.65-1.04),P=0.11,未达统计学显著。阿帕贝特组因肝酶升高停药35例(2.9%),安慰剂组11例(0.9%)。
要点
- 在近期急性冠脉综合征合并2型糖尿病及低高密度脂蛋白胆固醇患者中,阿帕贝特100 mg口服每日两次联合标准治疗未显著降低主要不良心血管事件(HR 0.82,95%CI 0.65-1.04,P=0.11)。
- 中位随访26.5个月,阿帕贝特组主要终点发生125例(10.3%),安慰剂组149例(12.4%)。
- 阿帕贝特组停药114例(9.4%),安慰剂组69例(5.7%);因肝酶升高停药分别为35例(2.9%)与11例(0.9%)。
- 该研究纳入标准为急性冠脉综合征发生在前7至90天内、合并2型糖尿病且高密度脂蛋白胆固醇水平低。
适用人群与场景
- 近期(前7至90天内)发生急性冠脉综合征、合并2型糖尿病且高密度脂蛋白胆固醇水平低的患者。
处置流程与药物剂量
- 阿帕贝特100 mg口服每日两次,联合标准治疗,疗程至研究随访结束(中位随访26.5个月)。
- 匹配安慰剂口服每日两次,联合标准治疗。
研究设计与关键结果
- 随机、双盲、安慰剂对照试验,在13个国家190个中心开展,纳入2425例患者(平均年龄62岁,女性618例[25.6%]),2320例(95.7%)完成主要终点 ascertainment。
- 主要终点为心血管死亡、非致死性心肌梗死或卒中首次发生的复合终点;中位随访26.5个月,阿帕贝特组125例(10.3%) vs 安慰剂组149例(12.4%),HR 0.82(95%CI 0.65-1.04),P=0.11,未达统计学显著。
- 阿帕贝特组停药114例(9.4%) vs 安慰剂组69例(5.7%);因肝酶升高停药分别为35例(2.9%) vs 11例(0.9%)。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于近期急性冠脉综合征合并2型糖尿病及低高密度脂蛋白胆固醇患者,在标准治疗基础上加用阿帕贝特100 mg口服每日两次未显著降低主要不良心血管事件风险(HR 0.82,95%CI 0.65-1.04,P=0.11)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Bromodomain and extraterminal proteins are epigenetic regulators of gene transcription. Apabetalone is a selective bromodomain and extraterminal protein inhibitor targeting bromodomain 2 and is hypothesized to have potentially favorable effects on pathways related to atherothrombosis. Pooled phase 2 data suggest favorable effects on clinical outcomes.
OBJECTIVE: To test whether apabetalone significantly reduces major adverse cardiovascular events.
DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial, conducted at 190 sites in 13 countries. Patients with an acute coronary syndrome in the preceding 7 to 90 days, type 2 diabetes, and low high-density lipoprotein cholesterol levels were eligible for enrollment, which started November 11, 2015, and ended July 4, 2018, with end of follow-up on July 3, 2019.
INTERVENTIONS: Patients were randomized (1:1) to receive apabetalone, 100 mg orally twice daily (n = 1215), or matching placebo (n = 1210) in addition to standard care.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of time to the first occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke.
RESULTS: Among 2425 patients who were randomized (mean age, 62 years; 618 women [25.6%]), 2320 (95.7%) had full ascertainment of the primary outcome. During a median follow-up of 26.5 months, 274 primary end points occurred: 125 (10.3%) in apabetalone-treated patients and 149 (12.4%) in placebo-treated patients (hazard ratio, 0.82 [95% CI, 0.65-1.04]; P = .11). More patients allocated to apabetalone than placebo discontinued study drug (114 [9.4%] vs 69 [5.7%]) for reasons including elevations of liver enzyme levels (35 [2.9%] vs 11 [0.9%]).
CONCLUSIONS AND RELEVANCE: Among patients with recent acute coronary syndrome, type 2 diabetes, and low high-density lipoprotein cholesterol levels, the selective bromodomain and extraterminal protein inhibitor apabetalone added to standard therapy did not significantly reduce the risk of major adverse cardiovascular events.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02586155.
参考来源
- Ray KK, Nicholls SJ, Buhr KA, et al. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2020. PMID: 32219359. doi:10.1001/jama.2020.3308
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。